EIDD-1931 - Advanced Antiviral Therapy for Feline Infectious Peritonitis (FIP)

Our Capsules delivers pure EIDD-1931, the active antiviral metabolite of molnupiravir, in a formulation designed for feline physiology. EIDD-1931 does not require metabolization in the liver, thus significantly reducing liver stress typically associated with prolonged Molnupiravir (EIDD-2801) treatments. By using EIDD-1931 directly—rather than modifying human molnupiravir capsules— Our EIDD-1931 capsules provides a more potent, precise, and consistent veterinary-appropriate approach to FIP care, while significantly reducing any potential side effects associated with prolonged Molnupiravir treatments.

Purpose-Built Feline Formulation

Each capsule contains 15 mg of EIDD-1931, equivalent in activity to approximately 66 mg of molnupiravir (EIDD-2801).

This formulation is optimized for:

Feline metabolic rate

Gastrointestinal absorption profile

Reliable dose–response performance

The result is accurate, predictable antiviral activity with reduced variability compared to human-intended products.

Proven Antiviral Potency

Published research demonstrates that:

• EIDD-1931 exhibits up to 5.6× greater in-vitro antiviral potency compared with molnupiravir (EIDD-2801).

• EIDD-1931 demonstrates 7.3× higher potency than GS-441524 under similar test conditions.

This potency advantage enables therapeutic efficacy at lower milligram doses, supporting improved tolerability and rapid clinical response.

Reference:

Molnupiravir and Its Active Form, EIDD-1931, Show Potent Antiviral Activity Against Enterovirus Infections In Vitro and In Vivo. https://www.mdpi.com/1999-4915/14/6/1142

Comprehensive Support Across FIP Presentations

Our EIDD-1931 capsules are formulated for all major forms of FIP, including:

• Wet FIP (effusive)

• Dry FIP (non-effusive)

• Mixed or transitional presentations

Additional formulation benefits:

• Optimized for feline metabolism and tissue penetration

• Highly consistent blood-level performance

• Designed to support low relapse incidence when used according to veterinary guidance

Precision, Safety & Confidence in Every Dose

Your cat receives an advanced, veterinary-formulated antiviral designed for targeted and reliable performance:

• Scientifically grounded formulation

• Consistent mg-per-kg dosing

• No need to modify human medications

• Backed by modern antiviral research

Compared to human 200mg molnupiravir, our capsules provides a clearer, more controlled path to FIP recovery, supporting your cat’s return to comfort, vitality, and quality of life.